Switzerland's Basilea Pharmaceutica has received FDA fast track status for its experimental therapy for fungal infections. BAL8557 may help protect against a broad range of fungal infections, which are linked to a high death rate among patients with a weakened immune system. Basilea reported positive Phase II data on the drug last September.
"BAL8557 is our second late stage hospital anti-infective drug with fast track status, highlighting our commitment as a leading anti-infectives company to develop drugs for high medical need", said Basilea CEO Dr. Anthony Man.
- see this UPI report on BAL8557